Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

IDEXX Laboratories Stock Gains On Q4 Earnings Beat, Upbeat FY22 Outlook

IDEXX Laboratories Inc (NASDAQ:IDXX) reported Q4 revenues of $801 million, an increase of 11% Y/Y on a reported basis and 10.5% on an organic basis, beating the consensus of $784.43 million.

  • Fourth-quarter results reflect 13% reported and organic revenue gains in CAG Diagnostics recurring revenues. 
  • CAG Diagnostics capital instrument reported revenue growth of 18% (21% organic).
  • Expanded cloud-based software capability, drove veterinary software, services, and diagnostic imaging systems revenue growth of 30% as reported and 13% organically.
  • Q4 EPS was $1.89, a decrease of 6% Y/Y, and Comparable EPS was $1.83, up 12% Y/Y, beating the consensus of $1.71.
  • The gross profit margin expanded slightly from 56.8% to 57%. The operating margin decreased from 25.7% to 24.9%.
  • Guidance: IDEXX Laboratories expects FY22 revenue of $3.50 billion - $3.565 billion (consensus $3.54 billion), reflecting growth of 9% - 11% on a reported basis and 10% - 12% organically.
  • The company forecasts 10.5% - 12% reported growth and 12% - 14% organic growth in CAG Diagnostics recurring revenues. 
  • The company also expects EPS of $9.27 - $9.59, compared to the consensus of $9.39.
  • Price Action: IDXX shares are up 4.68% at $537.53 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.